title: Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008-2011.
abstract: Invasive pneumococcal disease (IPD) is a notifiable disease in the Region of Madrid. The 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for children and adults aged two years or over with a high risk of disease, and for all adults aged 60 and over. We describe the evolution of IPD incidence from 2008 to 2011 in people aged 60 years and over and PPV23 vaccine effectiveness (VE). VE is estimated using both the screening method and indirect cohort method. The incidence of IPD varied from 20.0 in 2008 to 15.2 per 100,000 inhabitants in 2011 (RR: 0.8; 95% CI: 0.6–0.9). Adjusted VE estimated with the screening method was 68.2% (95% CI: 56.2–76.9). VE with the Broome method was 44.5% (95% CI: 23.8–59.6) for all PPV23 serotypes, and 64.4% (95% CI: 45.2–76.8) for PPV23 serotypes not included in conjugate vaccines. VE was lower in patients aged 80 years and older (25.5%; 95% CI:-23.2 to 55.0) and those with highrisk medical conditions (31.7%; 95% CI: -2.2 to -54.4). Adjusted VE was 44.5% (95% CI: 19.4-61.8) within 5 years of vaccination and 32.5% (95% CI: -5.6 to 56.9) after 5 years. These results are compatible with current recommendations for PPV23.
authors.affiliation: Direccion General de Atencion Primaria, Subdireccion de Promocion de la Salud y Prevencion, Consejeria de Sanidad, Comunidad de Madrid, Spain.
authors.forename: M A
authors.initials: MA
authors.lastname: Gutierrez Rodriguez
authors.forename: M A
authors.initials: MA
authors.lastname: Ordobas Gavin
authors.forename: L
authors.initials: L
authors.lastname: Garcia-Comas
authors.forename: J C
authors.initials: JC
authors.lastname: Sanz Moreno
authors.forename: E
authors.initials: E
authors.lastname: Cordoba Deorador
authors.forename: M D
authors.initials: MD
authors.lastname: Lasheras Carbajo
authors.forename: J A
authors.initials: JA
authors.lastname: Taveira Jimenez
authors.forename: F
authors.initials: F
authors.lastname: Martin Martinez
authors.forename: D
authors.initials: D
authors.lastname: Iniesta Fornies
authors.forename: A
authors.initials: A
authors.lastname: Arce Arnaez
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology; D011159:Population Surveillance; D012306:Risk; D012621:Seasons; D017678:Sex Distribution; D013030:Spain / Q000453:epidemiology; D013296:Streptococcus pneumoniae / Q000145:classification* / Q000276:immunology / Q000302:isolation & purification; D016896:Treatment Outcome; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000008:administration & dosage
chemical_list: C414006:23-valent pneumococcal capsular polysaccharide vaccine; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate